6mba

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 6mba is ON HOLD until Paper Publication
+
==Crystal Structure of Human Nav1.4 CTerminal Domain in Complex with apo Calmodulin==
-
 
+
<StructureSection load='6mba' size='340' side='right'caption='[[6mba]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
-
Authors: Yoder, J., Gabelli, S.B., Amzel, L.M.
+
== Structural highlights ==
-
 
+
<table><tr><td colspan='2'>[[6mba]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MBA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MBA FirstGlance]. <br>
-
Description: Crystal Structure of Human Nav1.4 CTerminal Domain in Complex with apo Calmodulin
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CO3:CARBONATE+ION'>CO3</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
-
[[Category: Unreleased Structures]]
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mba FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mba OCA], [http://pdbe.org/6mba PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mba RCSB], [http://www.ebi.ac.uk/pdbsum/6mba PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mba ProSAT]</span></td></tr>
-
[[Category: Amzel, L.M]]
+
</table>
-
[[Category: Gabelli, S.B]]
+
== Disease ==
 +
[[http://www.uniprot.org/uniprot/SCN4A_HUMAN SCN4A_HUMAN]] Postsynaptic congenital myasthenic syndromes;Paramyotonia congenita of Von Eulenburg;Myotonia fluctuans;Hyperkalemic periodic paralysis;Acetazolamide-responsive myotonia;Myotonia permanens;Hypokalemic periodic paralysis. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. SCN4A mutations are the cause of an autosomal recessive neuromuscular disorder characterized by severe fetal hypokinesia, neonatal hypotonia and congenital myopathy of variable severity. The most severe clinical features include reduced or absent fetal movements, in-utero upper and lower limb contractures, talipes and hydrops, and intrauterine or early postnatal death. Mildly affected patients present with generalized hypotonia and weakness at birth or within the first few days of life, mild-to-moderate facial muscle weakness without ptosis, significant early respiratory and feeding difficulties, and skeletal abnormalities of the spine and palate. Symptoms improve over time in patients who survive infancy, resulting in gain of muscle strength and motor skills and concomitant resolution of early respiratory and feeding difficulties. In contrast to other SCN4A-related channelopathies, affected individuals manifest in-utero or neonatal onset of permanent muscle weakness, rather than later-onset episodic muscle weakness.<ref>PMID:26700687</ref>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/SCN4A_HUMAN SCN4A_HUMAN]] This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeletal muscle.<ref>PMID:15318338</ref> <ref>PMID:16890191</ref> [[http://www.uniprot.org/uniprot/CALM1_RAT CALM1_RAT]] Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding. Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis. Mediates calcium-dependent inactivation of CACNA1C. Positively regulates calcium-activated potassium channel activity of KCNN2.[UniProtKB:P62158]
 +
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Large Structures]]
 +
[[Category: Amzel, L M]]
 +
[[Category: Gabelli, S B]]
[[Category: Yoder, J]]
[[Category: Yoder, J]]
 +
[[Category: Calmodulin]]
 +
[[Category: Calmodulin-binding protein]]
 +
[[Category: Membrane protein]]
 +
[[Category: Scn4a]]
 +
[[Category: Voltage gated sodium channel]]

Revision as of 07:25, 10 April 2019

Crystal Structure of Human Nav1.4 CTerminal Domain in Complex with apo Calmodulin

PDB ID 6mba

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools